Thursday, July 30

Browsing: BRCAMutated

Treatments

Personalized Treatment Plans for Certain Patients with BRCA-Mutated mCRPC

By NewsCancerApril 8, 20260

This article is sponsored by AstraZeneca. Dr George was compensated by AstraZeneca for his participation.Metastatic castration-resistant prostate cancer (mCRPC) remains…

Support

FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer

By NewsCancerFebruary 25, 20260

The FDA has granted fast track designation to ART6043 plus olaparib (Lynparza) for patients with germline BRCA-mutated HER2-negative locally advanced…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Browsing: BRCAMutated

Personalized Treatment Plans for Certain Patients with BRCA-Mutated mCRPC

FDA Grants Fast Track Designation to ART6043/Olaparib in BRCA-Mutated, HER2– Breast Cancer

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Linvoseltamab Data and Clinical Perspectives in Relapsed/Refractory Multiple Myeloma

Latest Post

Relapsed childhood cancers show genomic scars left by previous therapy

Introduction to BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma

Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer

Subscribe to Updates

What's Hot

Browsing: BRCAMutated